12th -
13th
February 2025
February 2025 |
Switzerland
ENHANCING SPEED & QUALITY IN CELL & GENE THERAPY MANUFACTURING FOR THE DACH REGION
EVENT CONCEPT
The landscape of cell and gene therapy manufacturing is experiencing a transformative evolution, fueled by advancements in technology and process optimization. This shift holds the promise of revolutionizing the production of therapies aimed at curing previously incurable diseases. Regulatory milestones, such as FDA approvals for novel manufacturing techniques and breakthrough therapies, highlight the significant progress within the field.
The emergence of innovative manufacturing platforms, including bioreactors, in-vivo cell engineering, and 3D cultures, is reshaping the way therapies are produced. These advancements, coupled with the potential of universal donor iPSC and CRISPR-based manufacturing techniques, are driving dynamism and scalability in the manufacturing process. However, alongside these breakthroughs, the manufacturing sector faces strategic challenges throughout the commercialization journey. From navigating regulatory compliance to optimizing production costs and ensuring quality control, addressing these hurdles is imperative to fully harness the transformative potential of cell and gene therapies.
We are thrilled to invite you to the Cell & Gene Therapy Manufacturing Summit 2025, where industry leaders and experts will converge to explore the forefront of CGT development and manufacturing. We will cover topics such as innovations in upstream and downstream processing, precision analytics, and efficient distribution. Expert panels will delve into cutting-edge bioprocessing and cell therapy manufacturing innovations. Your participation will help drive the future of CGT. We look forward to seeing you there!
WHAT TO EXPECT:
Explore different approaches of preclinical and clinical development such as proof-of-concept studies and extensive clinical research along with the latest developments in safety and efficacy, designing and implementing early-phase clinical trials and strategies for patient selection and recruitment. Learn about the pivotal role these processes play in ensuring that cell and gene therapies can be made available to patients as safe and effective treatment options.
Gain the current insights on cell and gene therapy manufacturing, strategies to streamline the manufacturing processes for improved efficiency and reduced cost along with techniques in cell expansion, cell culture and vector production. Find out how these practices accelerate the translation of scientific advancements into robust and reliable manufacturing processes for cell and gene therapies.
Review our collection of case studies highlighting significant achievements in the field of cell and gene therapy from across Europe, such as the development and commercialization of Strimvelis, and the clinical outcomes of Kymriah. These case studies will provide valuable insights for researchers, clinicians, and industry professionals engaged in the development and application of these transformative therapies.
Delve into our interactive and informative roundtable discussions which will feature topics from the Lessons from Cell and Gene Therapy Clinical Trials, Technology and Innovation in Cell and Gene Therapy, Overcoming Challenges in Commercialization along with Collaboration and Partnerships, Addressing Safety and Efficacy Concerns and The Future of Cell and Gene Therapy to name a few. Facilitated by industry experts, our discussions will provide an opportunity for delegates and speakers to network and connect while gaining the latest and more relevant insights into the cell and gene therapy industry.
Identify the advancements in gene editing tools, such as CRISPR/Cas9, that have significantly enhanced the precision and effectiveness of treatments by allowing for precise gene corrections, insertions, or deletions, offering unprecedented opportunities to address genetic diseases at their root cause and the advancements in vector design that have improved the delivery of therapeutic genes to target cells.
Learn about the novel therapies that aim to overcome existing limitations and expand the scope of treatment options for various diseases. Cutting-edge technologies, RNA-based therapeutics and advanced cell engineering are a few of the key innovations included, that are paving the way for more precise and targeted interventions. Find out how these next-generation treatments are poised to provide personalized, durable, and curative solutions for patients, offering hope for improved clinical outcomes and transforming the landscape of healthcare.
Early Bird (valid until 31 October 2024)
£1050.00 ex VAT
Standard Rate (valid from 01 November - 31 January 2025)
£1250.00 ex VAT
Final Call (valid from 01 February 2025 - 10 February 2025)
£1450.00 ex VAT
*Local Biopharma and Academia pricing is intended for Biopharma companies headquartered in the DACH region, as well as for Academic and Research Institutes
**Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
Early Bird (valid until 31 October 2024) £1350.00 ex VAT Standard Rate(valid from 01 November - 31 January 2025) £1550.00 ex VAT Final Call (valid from 01 February 2025 - 10 February 2025) £1750.00 ex VAT *International Biopharma pricing is intended for Biopharmas headquartered outside the DACH region **Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
Early Bird (valid until 31 October 2024)
£2250.00 ex VAT
Standard Rate(valid from 01 November - 31 January 2025)
£2450.00 ex VAT
Final Call (valid from 01 February 2025 - 10 February 2025)
£2650.00 ex VAT
*Big Pharma Pricing is intended for global pharmaceutical companies focused on drug development, research, and healthcare solutions
**Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
Early Bird (valid until 31 October 2024)
£1050.00 ex VAT
Standard Rate (valid from 01 November - 31 January 2025)
£1250.00 ex VAT
Final Call (valid from 01 February 2025 - 10 February 2025)
£1450.00 ex VAT
*Local Biopharma and Academia pricing is intended for Biopharma companies headquartered in the DACH region, as well as for Academic and Research Institutes
**Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
Early Bird (valid until 31 October 2024) £1350.00 ex VAT Standard Rate(valid from 01 November - 31 January 2025) £1550.00 ex VAT Final Call (valid from 01 February 2025 - 10 February 2025) £1750.00 ex VAT *International Biopharma pricing is intended for Biopharmas headquartered outside the DACH region **Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
Early Bird (valid until 31 October 2024)
£2250.00 ex VAT
Standard Rate(valid from 01 November - 31 January 2025)
£2450.00 ex VAT
Final Call (valid from 01 February 2025 - 10 February 2025)
£2650.00 ex VAT
*Big Pharma Pricing is intended for global pharmaceutical companies focused on drug development, research, and healthcare solutions
**Value Added Tax (VAT) exemptions will be applied where applicable in accordance with relevant regulations
IMAPAC is the go-to holistic producer of live events, biopharma data and digital marketing solutions for the global biopharmaceutical industry.
© 2024 Imapac. All rights reserved. Trade marks are owned by or licensed to imapac.